Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A Novel Antibody-Drug Conjugate for Targeting Tumor-Associated Macrophages in Solid Tumors

Project description

Innovative Antibody-Drug Conjugate for macrophage depletion in tumours

Tumour-Associated Macrophages (TAMs) within the Tumour Microenvironment (TME) play a significant role in tumour progression and immune evasion, necessitating the development of novel treatments. The ERC-funded TAM-AdaCT project seeks to pioneer an Antibody-Drug Conjugate (ADC) specifically for macrophage depletion within the TME. Concentrating on breast cancer and solid tumours, the proposed ADC will directly target these macrophages, effectively depleting them and fostering a more conducive environment for tumour eradication. The project aims to produce optimised ADCs capable of precisely targeting and depleting TAMs within the TME. It will validate ACC efficacy in preclinical models, assess its potential for human application, analyse its intellectual property landscape, and devise a strategy for commercial development.

Objective

"The project is focused on the development of a groundbreaking Antibody-Drug Conjugate (ADC) specifically designed for macrophage depletion in the Tumor Microenvironment (TME). With a primary focus on breast cancer and solid tumors, this initiative represents a paradigm shift in cancer therapeutics.

The presence of Tumor-Associated Macrophages (TAMs) in the TME has been identified as a significant factor in tumor progression and immune evasion. Our proposed ADC will directly target these macrophages, effectively depleting them and thereby creating a more favorable environment for tumor eradication.

The primary objectives of this project are as follows:

1. To synthesise and optimise ADCs for specific targeting and depletion of TAMs in the TME.
2. To demonstrate the efficacy of the ADC in preclinical models, establishing its potential for human application.
3. To perform a thorough ""freedom to operate"" analysis, ensuring that the ADC technology does not infringe upon existing intellectual property rights.
4. To establish a detailed plan for the commercial development of this ADC, outlining steps for regulatory approval, manufacturing scalability, and market entry.

By achieving these objectives, we aim to propel this project from the conceptual stage to a viable, commercialisable medical solution. The successful implementation of this ADC has the potential to revolutionise cancer treatment, offering a targeted approach that could significantly improve patient outcomes. The support of ERC Proof of Concept Grant will be pivotal in transitioning this transformative technology from the laboratory to the marketplace, ultimately changing the landscape of cancer therapeutics.

The strategic positioning of Zelula Biopharma (Host Institution) as a spin-off of CIC bioGUNE adds substantial value to this project, leveraging a unique blend of resources, academic research excellence and entrepreneurial agility to accelerate the transition from lab to market."

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

ADAPTAM THERAPEUTICS SL
Net EU contribution
€ 150 000,00
Address
PASEO DE MIRAMON 170 PLANTA 3
20014 SAN SEBASTIAN
Spain
SME
Yes
Region
Noreste País Vasco Gipuzkoa
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data

Beneficiaries (1)